ID: ALA343770

Max Phase: Preclinical

Molecular Formula: C26H25Cl2N3O

Molecular Weight: 466.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)cc(-c2ccc(Cl)cc2)c1O

Standard InChI:  InChI=1S/C26H25Cl2N3O/c1-3-31(4-2)16-18-13-21(15-23(26(18)32)17-5-7-19(27)8-6-17)30-24-11-12-29-25-14-20(28)9-10-22(24)25/h5-15,32H,3-4,16H2,1-2H3,(H,29,30)

Standard InChI Key:  ZXODOMROLXVJNM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 466.41

Molecular Weight (Monoisotopic): 465.1375

AlogP: 7.50

#Rotatable Bonds: 7

Polar Surface Area: 48.39

Molecular Species: BASE

HBA: 4

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.92

CX Basic pKa: 10.27

CX LogP: 5.76

CX LogD: 4.42

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.28

Np Likeness Score: -0.99

References

1. Werbel LM, Cook PD, Elslager EF, Hung JH, Johnson JL, Kesten SJ, McNamara DJ, Ortwine DF, Worth DF..  (1986)  Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.,  29  (6): [PMID:3712383] [10.1021/jm00156a009]

2. Acharya BN, Kaushik MP.  (2007)  Pharmacophore-based predictive model generation for potent antimalarials targeting haem detoxification pathway,  16  (5): [10.1007/s00044-007-9025-8]

Source

Source(1):

• Scientific Literature